Blood

Global Blood Warmer Market Projected to Reach USD 2.01 Billion by 2030, Surging at a Strong CAGR of 8.47% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Health, Medical Supplies, Medical Devices, Ageing, Temperature, Power Pack, IV, Hypothermia, Prevalence, Maintenance, Power pack, Injury, Growth, COVID-19, Risk, Hospital, Thermoregulation, Blood, USD, Accident, Compound annual growth rate, Pharmaceutical industry

The global blood warmer market is on track to reach a substantial size, projected to hit USD 2.01 billion by 2030, registering a robust Compound Annual Growth Rate (CAGR) of 8.47%.

Key Points: 
  • The global blood warmer market is on track to reach a substantial size, projected to hit USD 2.01 billion by 2030, registering a robust Compound Annual Growth Rate (CAGR) of 8.47%.
  • The global blood warmer market is experiencing unprecedented growth, driven by an increase in road accidents, injuries, and the rising prevalence of hypothermia cases.
  • North America leads the global blood warmer market, accounting for the highest chunk of market revenue.
  • The demand for infusion therapy surged significantly during this period, driving the need for blood warmer devices.

Global Monoclonal Antibody Diagnostic Reagent Market Analysis Report 2023-2028: Increasing Availability of POCT, Growing Use of Multiplexed Assays, & Development Of New mAB Therapies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Health, Pharmaceutical, Ageing, US, Biomarker, Therapy, Antigen, Prevalence, Conditional sentence, Point-of-care testing, ELISA, Research, Protein, POCT, Growth, Urine, Virus, Neoplasm, COVID-19, Antibody, Cancer, Blood, Infection, Investment, Patient, Diagnosis, Mab, Vaccine, Medical imaging, Pharmaceutical industry, Application

The global monoclonal antibody diagnostic reagent market value is projected to grow at a CAGR of 13.25%, during the forecast period of 2023-2028.

Key Points: 
  • The global monoclonal antibody diagnostic reagent market value is projected to grow at a CAGR of 13.25%, during the forecast period of 2023-2028.
  • The market for Monoclonal Antibody Diagnostic Reagents is poised for significant growth, driven by a robust pipeline of monoclonal antibody therapeutics in development.
  • Global Monoclonal Antibody Diagnostic Reagent Market Dynamics:
    Growth Drivers: Monoclonal antibody diagnostic reagents aid in the early identification and accurate diagnosis of many cancers.
  • Global Monoclonal Antibody Diagnostic Reagent Market: An Analysis
    Global Monoclonal Antibody Diagnostic Reagent Market: An Overview
    Global Monoclonal Antibody Diagnostic Reagent Market by Test (Enzyme Linked Immunosorbent, Double Antigen Sandwich Chemiluminescence Method, Assay Recombinant Immunoblot and Dot-immunogold Filtration Assay)
    Global Monoclonal Antibody Diagnostic Reagent Market by Application (Tumor Monitoring, Virus Detection, Hormones Diagnosis and Others)
    Global Monoclonal Antibody Diagnostic Reagent Market by Region (North America, Europe, Asia Pacific and Rest of the World)
    Global Monoclonal Antibody Diagnostic Reagent Market: Tests Analysis
    Global Monoclonal Antibody Diagnostic Reagent Market: Tests Overview
    Global Monoclonal Antibody Diagnostic Reagent Market: Application Analysis
    Global Monoclonal Antibody Diagnostic Reagent Market: Application Overview

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody

Retrieved on: 
Wednesday, October 18, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Mass General Brigham, Buprenorphine, Opioid use disorder, Harvard Medical School, IND, Drug, McLean Hospital, Assistant, U.S. government and smoking cessation, Psychiatry, Doctor of Philosophy, Naltrexone, Methadone, Development, OUD, National Institute on Drug Abuse, NIDA, Immunoglobulin G, Research and development, Blood, Brain, Mass, Therapy, Fentanyl, Bangladesh Technical Education Board, Pharmaceutical industry

The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.

Key Points: 
  • The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.
  • Through different delivery methods, the platform can be optimized to potentially protect against overdose, reverse overdose, and treat fentanyl-related opioid use disorder (OUD).
  • “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programs,” said Andy Barrett, PhD, Chief Scientific Officer at Cessation Therapeutics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries

Retrieved on: 
Wednesday, October 18, 2023
Health, Other Health, Other Science, Pharmaceutical, Science, Biotechnology, Metabolic acidosis, Rickets, Multimedia, Growth, Urine, Acid, Kidney, Partnership, Kidney disease, Blood, Traction, Renal tubular acidosis, Patient, Pharmaceutical industry

Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced that it has expanded its commercial partnership with Paris-based specialty pharmaceutical company Advicenne for Sibnayal®.

Key Points: 
  • Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced that it has expanded its commercial partnership with Paris-based specialty pharmaceutical company Advicenne for Sibnayal®.
  • Today’s announcement extends Avanzanite’s exclusive commercialization and distribution rights into three additional European countries, including Ireland, Cyprus and Malta.
  • The condition leads to stunted growth in children, brittle bones or rickets, kidney stones and life-threatening hypokalemia.
  • Announced in February 2023 , the original geographic scope of the partnership included Germany, Austria, Switzerland and Greece.

AI Diagnostic Platform Company Noul, unveils the result of Malaria study in Ethiopia and Ghana

Retrieved on: 
Monday, October 23, 2023
Plasmodium falciparum, Research, Real-time, Trial of the century, Global health, Exhibition, Incidence, University of Notre Dame, Parasitism, Korea Human Rights Foundation, History, Prevalence, Infection, Malaria, UNITAID, RDT, R, Society, Artificial intelligence, Plasmodium vivax, Tropical medicine, Hematological Cancer Research Investment and Education Act, Clinical trial, Diagnosis, Risk, Annual report, Partnership, University of Science and Technology, Annual general meeting, Blood, University, Public, American Society of Tropical Medicine and Hygiene, Patient, University of Gondar, Pharmaceutical industry, Medical imaging, Medical device, Typhoon Noul (2015), Plasmodium, Hygiene

In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.

Key Points: 
  • In the study, the scientists compared the sensitivity and specificity of the qPCR with those of miLab™, field microscopy, and Rapid Diagnostic Test (RDT) respectively.
  • Diagnosis of P. falciparum infections included cases with hrp2/hrp3 gene deletion with renders parasites 'invisible' to common rapid diagnostic tests.
  • Also, the diagnostic results of miLab™ in P. falciparum infected patients with hrp2/hrp3 gene deletion have been released.
  • This new study in Ethiopia and Ghana confirmed the clinical performance of miLab™ as a reliable new tool in the diagnosis of P. falciparum and P. vivax malaria.

Memorial Cardiac and Vascular Institute Reunites Patients with Caregivers that Saved Their Lives

Retrieved on: 
Monday, October 23, 2023
Ventricular septal defect, Abbott, Memorial Hermann Health System, Heart, Memorial Regional Hospital (Florida), Courage, VAD, Twin, Cardiology, Multimedia, Caregiver, Blood, Electrophysiology, Cancer, Nursing, Patient, Heart failure, Coma, Medical device, Management, Dentistry, Hospital, Memorial

HOLLYWOOD, Fla., Oct. 23, 2023 /PRNewswire-PRWeb/ -- An event recently hosted by Memorial Cardiac and Vascular Institute reunited heart failure patients with the caregivers that provided life-saving treatment, all to celebrate a milestone 10 years in the making.

Key Points: 
  • HOLLYWOOD, Fla., Oct. 23, 2023 /PRNewswire-PRWeb/ -- An event recently hosted by Memorial Cardiac and Vascular Institute reunited heart failure patients with the caregivers that provided life-saving treatment, all to celebrate a milestone 10 years in the making.
  • Their presence was a tangible reminder of the impact of the 75 VADs the Memorial program has implanted since it began in 2013.
  • 31-year-old Jade Abbott was one of the current patients in attendance to thank, she said, the team she 'owes her life to.'
  • Part of Memorial Healthcare System , the cardiac and vascular institute is South Florida's only Comprehensive Care Center accredited by the Adult Congenital Heart Association.

Allison-Smith Celebrates 80 Years of Innovation / Georgia firm experiences continued growth through a culture of entrepreneurship, innovation and problem solving

Retrieved on: 
Monday, October 23, 2023
Norfolk, National Association, Associated Builders and Contractors, General contractor, National Electrical Contractors Association, Allison Smith, Weather, BOMA, NCR, Children's Healthcare of Atlanta, Tokyo Disney Resort, Microsoft, Construction, Coda, Workforce, Intercontinental Exchange, Automotive Executive of the Year Award, Entrepreneurship, Mentorship, University, Trust, Growth, Cox Media Group, Building Owners and Managers Association, Problem solving, Main campus of the Georgia Institute of Technology, Georgia State University, Blood, Cisco, Culture, Safety, NECA, American Management Association, Longevity, Management

ATLANTA, Oct. 23, 2023 /PRNewswire-PRWeb/ -- ALLISON-SMITH CELEBRATES 80 YEARS OF INNOVATION

Key Points: 
  • Georgia firm experiences continued growth through a culture of entrepreneurship, innovation and problem solving.
  • Founded in Georgia in 1943, Allison-Smith Company is proud to celebrate a remarkable milestone - 80 years in business.
  • The firm's longevity is credited to a company culture that is rooted in entrepreneurship, innovation, and problem solving.
  • Allison-Smith has also lent its services to institutions like the Georgia Institute of Technology, the University of Georgia, and Georgia State.

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

Retrieved on: 
Monday, October 23, 2023
NHS foundation trust, The Royal Marsden NHS Foundation Trust, Real-time, Plasma, Genomics, NYSE, ESMO, Leukemia, Biomarker, Nucleic acid thermodynamics, Chromatin immunoprecipitation, Hereditary nonpolyposis colorectal cancer, Colorectal cancer, Chromatin, PCR, Research, Science, Neoplasm, FIT, Volition, Oncology, Blood, European Society for Medical Oncology, Liquid biopsy, Chemistry, Royal Marsden Hospital, Automation, Translational Genomics Research Institute, CTCF, DNA, Vaccine, Medical imaging, Coal, Cancer

Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.

Key Points: 
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.
  • Removal of normal DNA obviates expensive and time-consuming DNA sequencing and bioinformatics allowing for rapid, cost-effective detection in a routine blood test."
  • Volition tested the new method in a first small clinical experiment and detected a range of liquid and other cancers, including at early stage I disease.
  • Volition has organized a data insights webinar on Thursday 26th October at 10.30 AM U.S. Eastern to provide more information about the new cancer detection method.

Global Internet of Things (IoT) Sensors in Healthcare Market Report 2022-2028 with 2023 as the Base Year Featuring TE connectivity, STMicroelectronics, Analog Devices, Microchip, & On Semiconductor

Retrieved on: 
Monday, October 23, 2023
ECG, Patent, ESG, Prevalence, Face, Atrial fibrillation, Conditional sentence, Diabetes, Acquisition, Health, Internet, Artificial intelligence, Apple Watch, Environment, Growth, Apple, Blood, Insight, AI, Investment, Customer service, Pet industry, Retail, Medical imaging, Medical device, Pharmaceutical industry, Marketing, Internet of things, Health care

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- The "Internet of Things (IoT) Sensors in Healthcare: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 23, 2023 /PRNewswire/ -- The "Internet of Things (IoT) Sensors in Healthcare: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering.
  • Global Internet of Things (IoT) Sensors in Healthcare market is projected to reach a value of $8.6 billion by 2028 from $2.9 billion in 2023, growing at a CAGR of 24.6%
    The current report offers a detailed picture of IoT sensors in the healthcare market.
  • The rapid growth of the market for IoT sensors in healthcare is expected to continue during the forecast period.
  • Wearable gadgets such as remote monitoring devices, smartwatches and fitness trackers frequently utilize Internet of Things (IoT) sensors.

Olympus Announces Two New Category I CPT Codes for the iTind Procedure

Retrieved on: 
Friday, October 20, 2023
Patient, Ageing, Olympus Corporation, Health care, Medicare, American Medical Association, Physician, LUTS, AMA, Urine, Blood, Urinary tract infection, CPT, Olympus, BPH, UNITE, Centers for Medicare & Medicaid Services, CMS, Health insurance, Medicaid

The release of these two new Category I CPT codes represents a major reimbursement milestone for the iTind procedure that will standardize and streamline the reimbursement process.

Key Points: 
  • The release of these two new Category I CPT codes represents a major reimbursement milestone for the iTind procedure that will standardize and streamline the reimbursement process.
  • CPT codes are granted and maintained by the AMA CPT Editorial Panel and are used by government payers, including Medicare and Medicaid, and commercial health plans to describe healthcare services and procedures for reimbursement.
  • The two new CPT codes for the iTind procedure will go into effect on or after January 1, 2025.
  • Patients who are candidates for the iTind procedure may be assisted in navigating medical insurance systems through the Olympus UNITE program.